☰

Rhine R. Shen, Ph.D. - Publications

Affiliations: 
2006 University of California, Los Angeles, Los Angeles, CA 
Tree Info Similar researchers PubMed Report error

23 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Locke FL, Filosto S, Chou J, Vardhanabhuti S, Perbost R, Dreger P, Hill BT, Lee C, Zinzani PL, Kröger N, López-Guillermo A, Greinix H, Zhang W, Tiwari G, Budka J, ... ... Shen R, et al. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma. Nature Medicine. PMID 38233586 DOI: 10.1038/s41591-023-02754-1  0.411
2023 Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff PJ, Flinn IW, Farooq U, ... ... Shen RR, et al. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1). Blood. PMID 36821768 DOI: 10.1182/blood.2022018893  0.37
2020 Foubert P, Srihari S, Le Textier L, Shen R, Forozan F, Smith C, Khanna R, Aftab B. Gene expression profiling and TCR diversity of ATA188, a Pre-manufactured, Allogeneic Epstein-Barr Virus-targeted T-cell Immunotherapy for Patients with Multiple Sclerosis Cytotherapy. 22: S115. DOI: 10.1016/J.Jcyt.2020.03.212  0.36
2019 Shen RR, Pham CD, Wu MM, Munson DJ, Aftab BT. Abstract 2310: Functional demonstration of CD19 chimeric antigen receptor (CAR) engineered Epstein-Barr virus (EBV) specific T cells: An off-the-shelf, allogeneic CAR T-cell immunotherapy platform Cancer Research. 79: 2310-2310. DOI: 10.1158/1538-7445.Am2019-2310  0.404
2015 Luo LY, Kim E, Cheung HW, Weir BA, Dunn GP, Shen RR, Hahn WC. The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer. Molecular Cancer Research : McR. 13: 502-9. PMID 25368431 DOI: 10.1158/1541-7786.Mcr-14-0407  0.401
2015 Shen RR, Zhou AY, Kim E, O'Connell JT, Hagerstrand D, Beroukhim R, Hahn WC. TRAF2 is an NF-κB-activating oncogene in epithelial cancers. Oncogene. 34: 209-16. PMID 24362534 DOI: 10.1038/Onc.2013.543  0.375
2014 Zhu Z, Aref AR, Cohoon TJ, Barbie TU, Imamura Y, Yang S, Moody SE, Shen RR, Schinzel AC, Thai TC, Reibel JB, Tamayo P, Godfrey JT, Qian ZR, Page AN, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discovery. 4: 452-65. PMID 24444711 DOI: 10.1158/2159-8290.Cd-13-0646  0.349
2013 Hagerstrand D, Tong A, Schumacher SE, Ilic N, Shen RR, Cheung HW, Vazquez F, Shrestha Y, Kim SY, Giacomelli AO, Rosenbluh J, Schinzel AC, Spardy NA, Barbie DA, Mermel CH, et al. Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discovery. 3: 1044-57. PMID 23764425 DOI: 10.1158/2159-8290.Cd-12-0592  0.344
2013 Zhou AY, Shen RR, Kim E, Lock YJ, Xu M, Chen ZJ, Hahn WC. IKKε-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex. Cell Reports. 3: 724-33. PMID 23453969 DOI: 10.1016/J.Celrep.2013.01.031  0.385
2012 Shen RR, Zhou AY, Kim E, Lim E, Habelhah H, Hahn WC. IκB kinase ε phosphorylates TRAF2 to promote mammary epithelial cell transformation. Molecular and Cellular Biology. 32: 4756-68. PMID 23007157 DOI: 10.1128/Mcb.00468-12  0.403
2012 Creton S, Aardema MJ, Carmichael PL, Harvey JS, Martin FL, Newbold RF, O'Donovan MR, Pant K, Poth A, Sakai A, Sasaki K, Scott AD, Schechtman LM, Shen RR, Tanaka N, et al. Cell transformation assays for prediction of carcinogenic potential: state of the science and future research needs. Mutagenesis. 27: 93-101. PMID 21852270 DOI: 10.1093/Mutage/Ger053  0.346
2012 Zhou AY, Shen RR, Kim E, Chen Z, Hahn WC. Abstract 4863: Ubiquitination of the breast cancer oncogene IKKα is essential for transformation Cancer Research. 72: 4863-4863. DOI: 10.1158/1538-7445.Am2012-4863  0.383
2011 Shen RR, Hahn WC. Emerging roles for the non-canonical IKKs in cancer. Oncogene. 30: 631-41. PMID 21042276 DOI: 10.1038/Onc.2010.493  0.401
2009 Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM, Hahn WC, Cantley LC. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Molecular Cell. 34: 461-72. PMID 19481526 DOI: 10.1016/J.Molcel.2009.04.031  0.381
2009 Frank MJ, Dawson DW, Bensinger SJ, Hong JS, Knosp WM, Xu L, Balatoni CE, Allen EL, Shen RR, Bar-Sagi D, Martin GR, Teitell MA. Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas. Blood. 113: 2478-87. PMID 19147787 DOI: 10.1182/Blood-2008-05-156943  0.586
2007 Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 129: 1065-79. PMID 17574021 DOI: 10.1016/J.Cell.2007.03.052  0.406
2007 Pelling AE, Dawson DW, Carreon DM, Christiansen JJ, Shen RR, Teitell MA, Gimzewski JK. Distinct contributions of microtubule subtypes to cell membrane shape and stability. Nanomedicine : Nanotechnology, Biology, and Medicine. 3: 43-52. PMID 17379168 DOI: 10.1016/J.Nano.2006.11.006  0.529
2007 Dawson DW, Hong JS, Shen RR, French SW, Troke JJ, Wu YZ, Chen SS, Gui D, Regelson M, Marahrens Y, Morse HC, Said J, Plass C, Teitell MA. Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas. Oncogene. 26: 4243-52. PMID 17260020 DOI: 10.1038/Sj.Onc.1210211  0.692
2006 Shen RR, Ferguson DO, Renard M, Hoyer KK, Kim U, Hao X, Alt FW, Roeder RG, Morse HC, Teitell MA. Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation. Blood. 108: 1991-8. PMID 16728701 DOI: 10.1182/Blood-2006-02-001354  0.723
2003 Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D. TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood. 101: 5007-9. PMID 12576313 DOI: 10.1182/Blood-2002-10-3297  0.578
2003 French SW, Malone CS, Shen RR, Renard M, Henson SE, Miner MD, Wall R, Teitell MA. Sp1 transactivation of the TCL1 oncogene. The Journal of Biological Chemistry. 278: 948-55. PMID 12421830 DOI: 10.1074/Jbc.M207166200  0.543
2002 French SW, Hoyer KK, Shen RR, Teitell MA. Transdifferentiation and nuclear reprogramming in hematopoietic development and neoplasia. Immunological Reviews. 187: 22-39. PMID 12366680 DOI: 10.1034/J.1600-065X.2002.18703.X  0.675
2002 French SW, Shen RR, Koh PJ, Malone CS, Mallick P, Teitell MA. A modeled hydrophobic domain on the TCL1 oncoprotein mediates association with AKT at the cytoplasmic membrane. Biochemistry. 41: 6376-82. PMID 12009899 DOI: 10.1021/Bi016068O  0.567
Show low-probability matches.